



**In the Claims**

1. (Withdrawn) A block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:



wherein the non-fluorinated block has the following structure:




wherein  $R_1$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl, naphthyl,  $-\text{COOR}_3$ , and  $-\text{CONR}_3\text{R}_4$ ;

wherein  $R_2$  is selected from the group consisting of  $-\text{H}$ ,  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl, and naphthalenyl; and

wherein  $R_3$  and  $R_4$  are selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and -PEG.

2. (Withdrawn) The block copolymer of claim 1 having a formula of the following structure:




wherein  $R_1'$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ , -

$\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and -PEG, and

wherein  $\text{R}_2$  is selected from the group consisting of  $-\text{H}$  or  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl and naphthyl.


3. (Withdrawn) The block copolymer of claim 2 wherein  $\text{R}_1$  is  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or -PEG, and wherein  $\text{R}_2$  is  $-\text{H}$  or  $-\text{CH}_3$ .

4. (Withdrawn) A block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:




wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof.

5. (Withdrawn) A polymeric coating composition comprising a block copolymer which comprises a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:



wherein the non-fluorinated block has the following structure:




wherein  $R_1$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl, naphthyl,  $-\text{COOR}_3$ , and  $-\text{CONR}_3\text{R}_4$ ;

wherein  $R_2$  is selected from the group consisting of  $-\text{H}$ ,  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl, and naphthalenyl; and

wherein  $R_3$  and  $R_4$  are selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and -PEG.

6. (Withdrawn) The coating composition of claim 5 wherein the block copolymer has a formula of the following structure:




wherein  $R_1$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and -PEG, and

wherein  $R_2$  is selected from the group consisting of  $-\text{H}$  or  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl and naphthyl.

7. (Withdrawn) The coating composition of claim 6 wherein  $R_1$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , or -PEG, and

wherein  $R_2$  is  $-\text{H}$  or  $-\text{CH}_3$ .

8. (Withdrawn) A polymeric coating composition comprising a block copolymer which comprises a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:



wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof.

9. (Withdrawn) The coating composition of claim 5 further comprising a bioactive agent.

10. (Withdrawn) The coating composition of claim 6 further comprising a bioactive agent.

11. (Withdrawn) The coating composition of claim 7 further comprising a bioactive agent.

12. (Withdrawn) The coating composition of claim 8 further comprising a bioactive agent.

13. (Withdrawn) The coating composition of claim 9 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.


14. (Withdrawn) The coating composition of claim 10 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin,

Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.


15. (Withdrawn) The coating composition of claim 11 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

16. (Currently amended) An implantable device comprising a coating which comprises a block copolymer, the block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block is a poly(fluoroalkene).

17. (Original) The implantable device of claim 16, wherein the fluorinated block has the following structure:



wherein the non-fluorinated block has the following structure:




wherein  $R_1$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl, naphthyl,  $-\text{COOR}_3$ , and  $-\text{CONR}_3\text{R}_4$ ;

wherein  $R_2$  is selected from the group consisting of  $-\text{H}$ ,  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ , -phenyl, and naphthalenyl; and

wherein  $R_3$  and  $R_4$  are selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ , -

$\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and  $-\text{PEG}$ .

18. (Original) The implantable device of claim 17, wherein the block copolymer has a formula of the following structure:




wherein  $R_1$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , and  $-\text{PEG}$ , and

wherein  $R_2$  is selected from the group consisting of  $-\text{H}$  or  $-\text{CH}_3$ ,  $-\text{CF}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{phenyl}$  and  $-\text{naphthyl}$ .

19. (Currently amended) The implantable device of claim 18 wherein  $R_1$  is selected from the group consisting of  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_2\text{OH}$ , ~~or~~ and  $-\text{PEG}$ , and

wherein  $R_2$  is  $-\text{H}$  or  $-\text{CH}_3$ .

20. (Original) The implantable device of claim 16, wherein the fluorinated block has the following structure:



wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof.

21. (Original) The implantable device of claim 16, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

22. (Original) The implantable device of claim 17, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

23. (Original) The implantable device of claim 18, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

24. (Original) The implantable device of claim 19, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

25. (Original) The implantable device of claim 20, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

26. (Currently amended) The implantable device of claim 21, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, ~~Everolimus~~ everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

27. (Currently amended) The implantable device of claim 22, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, ~~Everolimus~~ everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

28. (Currently amended) The implantable device of claim 23, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, ~~Everolimus~~ everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

29. (Currently amended) The implantable device of claim 24, wherein the

bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, ~~Everolimus~~ everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

30. (Currently amended) The implantable device of claim 25, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, ~~Everolimus~~ everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

31. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 16.

32. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 17.

33. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 26.


34. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 27.

35. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 28.


36. (Withdrawn) A method of synthesizing a block copolymer comprising a



fluorinated block and at least a block of the following structure:



, comprising copolymerizing a monomer having the structure of



in the presence of a di-halo macromer,

wherein R<sub>1</sub> is selected from the group consisting of -CH<sub>3</sub>, -CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -phenyl, naphthyl, -COOR<sub>3</sub>, and -CONR<sub>3</sub>R<sub>4</sub>;

wherein R<sub>2</sub> is selected from the group consisting of -H, -CH<sub>3</sub>, -CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -phenyl, and naphthalenyl; and

wherein R<sub>3</sub> and R<sub>4</sub> are selected from the group consisting of -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, and -PEG, and

wherein the di-halo macromer is selected from the group consisting of di-chloro macromer, di-bromo macromer, di-iodo macromer and a combination thereof.

37. (Withdrawn) The method of claim 36 wherein the di-halo macromer is formed by polymerizing a fluorinated olefin in the presence of a dihalide.

38. (Withdrawn) The method of claim 37 wherein the fluorinated olefin is selected from the group consisting of vinylidene fluoride, hexafluoropropylene, tetrafluoroethylene, and a combination thereof.

39. (Withdrawn) The method of claim 38 wherein the di-halo macromer is prepared by polymerizing a mixture of vinylidene fluoride and 1,1,2,3,3,3-hexafluoropropylene in the presence of 1,2-diiodo-1,1,2,2-difluoroethylene.

40. (Withdrawn) The method of claim 39 the di-halo macromer has a structure of

